Nitric oxide (NO) is an important molecule that exerts multiple functions in biological systems. Because of the short-lived nature of NO, S-nitrosothiols (RSNOs) are believed to act as stable NO carriers. Recently, sulfhydryl (SH) containing macromolecules have been shown to be promising NO carriers. In the present study, we aimed to synthesize and characterize a potential NO carrier based on bovine Cu,Zn-superoxide dismutase (bSOD). To prepare S-nitrosated bSOD, the protein was incubated with S-nitrosoglutathione (GSNO) under varied experimental conditions. The results show that significant S-nitrosation of bSOD occurred only at high temperature (50 °C) for prolonged incubation time (>2 h). S-nitrosation efficiency increased with reaction time and reached a plateau at ~4 h. The maximum amount of NO loaded was determined to be about 0.6 mol SNO/mol protein (~30% loading efficiency). The enzymatic activity of bSOD, however, decreased with reaction time. Our data further indicate that NO functionality can only be measured in the presence of extremely high concentrations of Hg 2+ or when the protein was denatured by guanidine. Moreover, mildly acidic pH was shown to favor S-nitrosation of bSOD. A model based on unfolding and refolding of bSOD during preparation was proposed to possibly explain our observation.
References
[1]
Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J 2001, 357, 593–615.
[2]
Wink, D.A.; Mitchell, J.B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med 1998, 25, 434–456.
[3]
Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol 1996, 271, C1424–C1437.
[4]
Broniowska, K.A.; Hogg, N. The chemical biology of S-nitrosothiols. Antioxid. Redox. Signal 2012, 17, 969–980.
[5]
Thomas, D.D.; Jourd’heuil, D. S-nitrosation: Current concepts and new developments. Antioxid. Redox. Signal 2012, 17, 934–936.
[6]
Stamler, J.S.; Jaraki, O.; Osborne, J.; Simon, D.I.; Keaney, J.; Vita, J.; Singel, D.; Valeri, C.R.; Loscalzo, J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Sci. USA 1992, 89, 7674–7677.
[7]
Scharfstein, J.S.; Keaney, J.F., Jr; Slivka, A.; Welch, G.N.; Vita, J.A.; Stamler, J.S.; Loscalzo, J. In vivotransfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J. Clin. Invest 1994, 94, 1432–1439.
[8]
Jourd’heuil, D.; Hallen, K.; Feelisch, M.; Grisham, M.B. Dynamic state of S-nitrosothiols in human plasma and whole blood. Free Radic. Biol. Med 2000, 28, 409–417.
Doulias, P.T.; Greene, J.L.; Greco, T.M.; Tenopoulou, M.; Seeholzer, S.H.; Dunbrack, R.L.; Ischiropoulos, H. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. Proc. Natl. Acad. Sci. USA 2010, 107, 16958–16963.
[11]
Seth, D.; Stamler, J.S. The SNO-proteome: Causation and classifications. Curr. Opin. Chem. Biol 2011, 15, 129–136.
[12]
Foster, M.W. Methodologies for the characterization, identification and quantification of S-nitrosylated proteins. Biochim. Biophys. Acta 2011, 1820, 675–683.
[13]
Chen, Y.J.; Ku, W.C.; Lin, P.Y.; Chou, H.C.; Khoo, K.H.; Chen, Y.J. S-alkylating labeling strategy for site-specific identification of the s-nitrosoproteome. J. Proteome Res 2010, 9, 6417–6439.
[14]
Stamler, J.S.; Simon, D.I.; Osborne, J.A.; Mullins, M.E.; Jaraki, O.; Michel, T.; Singel, D.J.; Loscalzo, J. S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. USA 1992, 89, 444–448.
[15]
Marks, D.S.; Vita, J.A.; Folts, J.D.; Keaney, J.F., Jr; Welch, G.N.; Loscalzo, J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J. Clin. Invest 1995, 96, 2630–2638.
[16]
Ewing, J.F.; Young, D.V.; Janero, D.R.; Garvey, D.S.; Grinnell, T.A. Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. J. Pharmacol. Exp. Ther 1997, 283, 947–954.
[17]
Katsumi, H.; Nishikawa, M.; Ma, S.F.; Yamashita, F.; Hashida, M. Physicochemical, tissue distribution, and vasodilation characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo. J. Pharm. Sci 2004, 93, 2343–2352.
[18]
Katsumi, H.; Nishikawa, M.; Yamashita, F.; Hashida, M. Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J. Pharmacol. Exp. Ther 2005, 314, 1117–1124.
[19]
Ishima, Y.; Hiroyama, S.; Kragh-Hansen, U.; Maruyama, T.; Sawa, T.; Akaike, T.; Kai, T.; Otagiri, M. One-step preparation of S-nitrosated human serum albumin with high biological activities. Nitric Oxide 2010, 23, 121–127.
[20]
Ishima, Y.; Yoshida, F.; Kragh-Hansen, U.; Watanabe, K.; Katayama, N.; Nakajou, K.; Akaike, T.; Kai, T.; Maruyama, T.; Otagiri, M. Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin. Free Radic. Res 2011, 45, 1196–1206.
[21]
Ishima, Y.; Akaike, T.; Kragh-Hansen, U.; Hiroyama, S.; Sawa, T.; Suenaga, A.; Maruyama, T.; Kai, T.; Otagiri, M. S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding. J. Biol. Chem 2008, 283, 34966–34975.
[22]
Ishima, Y.; Kragh-Hansen, U.; Maruyama, T.; Otagiri, M. Albumin as a nitric oxide-traffic protein: Characterization, biochemistry and possible future therapeutic applications. Drug Metab. Pharmacokinet 2009, 24, 308–317.
[23]
Katayama, N.; Nakajou, K.; Komori, H.; Uchida, K.; Yokoe, J.; Yasui, N.; Yamamoto, H.; Kai, T.; Sato, M.; Nakagawa, T.; et al. Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug. J. Pharmacol. Exp. Ther 2008, 325, 69–76.
[24]
Katayama, N.; Nakajou, K.; Ishima, Y.; Ikuta, S.; Yokoe, J.; Yoshida, F.; Suenaga, A.; Maruyama, T.; Kai, T.; Otagiri, M. Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. Nitric Oxide 2010, 22, 259–265.
[25]
Ishima, Y.; Chen, D.; Fang, J.; Maeda, H.; Minomo, A.; Kragh-Hansen, U.; Kai, T.; Maruyama, T.; Otagiri, M. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. Bioconjug. Chem 2012, 23, 264–271.
[26]
McCord, J.M.; Fridovich, I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem 1969, 244, 6049–6055.
[27]
Rypniewski, W.R.; Mangani, S.; Bruni, B.; Orioli, P.L.; Casati, M.; Wilson, K.S. Crystal structure of reduced bovine erythrocyte superoxide dismutase at 1.9 A resolution. J. Mol. Biol 1995, 251, 282–296.
[28]
Carden, D.L.; Granger, D.N. Pathophysiology of ischaemia-reperfusion injury. J. Pathol 2000, 190, 255–266.
[29]
Kurose, I.; Wolf, R.; Grisham, M.B.; Granger, D.N. Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ. Res 1994, 74, 376–382.
[30]
Ferdinandy, P.; Schulz, R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol 2003, 138, 532–543.
[31]
Jung, O.; Marklund, S.L.; Geiger, H.; Pedrazzini, T.; Busse, R.; Brandes, R.P. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: In vivo and ex vivo evidence from ecSOD-deficient mice. Circ. Res 2003, 93, 622–629.
[32]
Katsumi, H.; Nishikawa, M.; Yasui, H.; Yamashita, F.; Hashida, M. Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. J. Control. Release 2009, 140, 12–17.
[33]
Konorev, E.A.; Kalyanaraman, B.; Hogg, N. Modification of creatine kinase by S-nitrosothiols: S-nitrosation vs. S-thiolation. Free Radic. Biol. Med 2000, 28, 1671–1678.
[34]
Giustarini, D.; Milzani, A.; Aldini, G.; Carini, M.; Rossi, R.; Dalle-Donne, I. S-nitrosation versus S-glutathionylation of protein sulfhydryl groups by S-nitrosoglutathione. Antioxid. Redox. Signal 2005, 7, 930–939.
[35]
Wolzt, M.; MacAllister, R.J.; Davis, D.; Feelisch, M.; Moncada, S.; Vallance, P.; Hobbs, A.J. Biochemical characterization of S-nitrosohemoglobin. Mechanisms underlying synthesis, no release, and biological activity. J. Biol. Chem 1999, 274, 28983–28990.
[36]
Barglow, K.T.; Knutson, C.G.; Wishnok, J.S.; Tannenbaum, S.R.; Marletta, M.A. Site-specific and redox-controlled S-nitrosation of thioredoxin. Proc. Natl. Acad. Sci. USA 2011, 108, E600–E606.
[37]
Singh, R.J.; Hogg, N.; Joseph, J.; Kalyanaraman, B. Mechanism of nitric oxide release from S-nitrosothiols. J. Biol. Chem 1996, 271, 18596–18603.
[38]
Stamler, J.S.; Toone, E.J. The decomposition of thionitrites. Curr. Opin. Chem. Biol 2002, 6, 779–785.
[39]
Gorren, A.C.; Schrammel, A.; Schmidt, K.; Mayer, B. Decomposition of S-nitrosoglutathione in the presence of copper ions and glutathione. Arch. Biochem. Biophys 1996, 330, 219–228.
[40]
Arnelle, D.R.; Stamler, J.S. NO+, NO？, and NO？ donation by S-nitrosothiols: Implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch. Biochem. Biophys 1995, 318, 279–285.
[41]
Hu, T.M.; Chou, T.C. The kinetics of thiol-mediated decomposition of S-nitrosothiols. Aaps. J 2006, 8, E485–E492.
[42]
Meyer, D.J.; Kramer, H.; Ozer, N.; Coles, B.; Ketterer, B. Kinetics and equilibria of S-nitrosothiol-thiol exchange between glutathione, cysteine, penicillamines and serum albumin. FEBS Lett 1994, 345, 177–180.
[43]
Cook, J.A.; Kim, S.Y.; Teague, D.; Krishna, M.C.; Pacelli, R.; Mitchell, J.B.; Vodovotz, Y.; Nims, R.W.; Christodoulou, D.; Miles, A.M.; et al. Convenient colorimetric and fluorometric assays for S-nitrosothiols. Anal. Biochem 1996, 238, 150–158.
[44]
Scorza, G.; Pietraforte, D.; Minetti, M. Role of ascorbate and protein thiols in the release of nitric oxide from S-nitroso-albumin and S-nitroso-glutathione in human plasma. Free Radic. Biol. Med 1997, 22, 633–642.
[45]
Hallewell, R.A.; Imlay, K.C.; Lee, P.; Fong, N.M.; Gallegos, C.; Getzoff, E.D.; Tainer, J.A.; Cabelli, D.E.; Tekamp-Olson, P.; Mullenbach, G.T.; et al. Thermostabilization of recombinant human and bovine CuZn superoxide dismutases by replacement of free cysteines. Biochem. Biophys. Res. Commun 1991, 181, 474–480.
[46]
Lepock, J.R.; Frey, H.E.; Hallewell, R.A. Contribution of conformational stability and reversibility of unfolding to the increased thermostability of human and bovine superoxide dismutase mutated at free cysteines. J. Biol. Chem 1990, 265, 21612–21618.
[47]
Fee, J.A.; Phillips, W.D. The behavior of holo- and apo-forms of bovine superoxide dismutase at low pH. Biochim. Biophys. Acta 1975, 412, 26–38.
[48]
Padgett, C.M.; Whorton, A.R. Cellular responses to nitric oxide: Role of protein S-thiolation/dethiolation. Arch. Biochem. Biophys 1998, 358, 232–242.
[49]
Ji, Y.; Akerboom, T.P.; Sies, H.; Thomas, J.A. S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione. Arch. Biochem. Biophys 1999, 362, 67–78.
[50]
Mohr, S.; Hallak, H.; de Boitte, A.; Lapetina, E.G.; Brune, B. Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem 1999, 274, 9427–9430.
[51]
Li, J.; Huang, F.L.; Huang, K.P. Glutathiolation of proteins by glutathione disulfide S-oxide derived from S-nitrosoglutathione. Modifications of rat brain neurogranin/RC3 and neuromodulin/GAP-43. J. Biol. Chem 2001, 276, 3098–3105.
[52]
Xian, M.; Chen, X.; Liu, Z.; Wang, K.; Wang, P.G. Inhibition of papain by S-nitrosothiols. Formation of mixed disulfides. J. Biol. Chem 2000, 275, 20467–20473.
[53]
Liu, Z.; Rudd, M.A.; Freedman, J.E.; Loscalzo, J. S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide. J. Pharmacol. Exp. Ther 1998, 284, 526–534.
[54]
Hogg, N. The kinetics of S-transnitrosation—A reversible second-order reaction. Anal. Biochem 1999, 272, 257–262.
[55]
Klatt, P.; Lamas, S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem 2000, 267, 4928–4944.
[56]
Beckman, J.S.; Minor, R.L., Jr; White, C.W.; Repine, J.E.; Rosen, G.M.; Freeman, B.A. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J. Biol. Chem. 1988, 263, 6884–6892.
[57]
Filipe, P.; Emerit, I.; Vassy, J.; Levy, A.; Huang, V.; Freitas, J. Cellular penetration of fluorescently labeled superoxide dismutases of various origins. Mol. Med 1999, 5, 517–525.
[58]
Chorny, M.; Hood, E.; Levy, R.J.; Muzykantov, V.R. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J. Control. Release 2010, 146, 144–151.
[59]
Hood, E.; Simone, E.; Wattamwar, P.; Dziubla, T.; Muzykantov, V. Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) 2011, 6, 1257–1272.
[60]
Yamakura, F.; Taka, H.; Fujimura, T.; Murayama, K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem 1998, 273, 14085–14089.
[61]
Demicheli, V.; Quijano, C.; Alvarez, B.; Radi, R. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. Free Radic. Biol. Med 2007, 42, 1359–1368.
[62]
Akhtar, M.W.; Sunico, C.R.; Nakamura, T.; Lipton, S.A. Redox Regulation of Protein Function via Cysteine S-Nitrosylation and Its Relevance to Neurodegenerative Diseases. Int. J. Cell Biol. 2012, doi:10.1155/2012/463756.
Fujiwara, N.; Nakano, M.; Kato, S.; Yoshihara, D.; Ookawara, T.; Eguchi, H.; Taniguchi, N.; Suzuki, K. Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J. Biol. Chem 2007, 282, 35933–35944.
[68]
Okado-Matsumoto, A.; Guan, Z.; Fridovich, I. Modification of cysteine 111 in human Cu,Zn-superoxide dismutase. Free Radic. Biol. Med 2006, 41, 1837–1846.
[69]
Stathopulos, P.B.; Rumfeldt, J.A.; Scholz, G.A.; Irani, R.A.; Frey, H.E.; Hallewell, R.A.; Lepock, J.R.; Meiering, E.M. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc. Natl. Acad. Sci. USA 2003, 100, 7021–7026.
[70]
Rumfeldt, J.A.; Stathopulos, P.B.; Chakrabarrty, A.; Lepock, J.R.; Meiering, E.M. Mechanism and thermodynamics of guanidinium chloride-induced denaturation of ALS-associated mutant Cu,Zn superoxide dismutases. J. Mol. Biol 2006, 355, 106–123.
[71]
Rumfeldt, J.A.; Lepock, J.R.; Meiering, E.M. Unfolding and folding kinetics of amyotrophic lateral sclerosis-associated mutant Cu,Zn superoxide dismutases. J. Mol. Biol 2009, 385, 278–298.
[72]
Antharavally, B.S.; Mallia, K.A.; Rangaraj, P.; Haney, P.; Bell, P.A. Quantitation of proteins using a dye-metal-based colorimetric protein assay. Anal. Biochem 2009, 385, 342–345.
[73]
Abernethy, J.L.; Steinman, H.M.; Hill, R.L. Bovine erythrocyte superoxide dismutase. Subunit structure and sequence location of the intrasubunit disulfide bond. J. Biol. Chem 1974, 249, 7339–7347.
